# Mike Lee

> Mike Lee is a Series A investor backing Apps and Biopharma. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 3
- Last investment: Jul 2019
- Lead investor: 33%
- Last updated: Aug 2026

Mike Lee is a Series A investor focused on Apps and Biopharma. Mike Lee

## Contacts

5 contacts available for Mike Lee: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/mike-lee-90ca?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Apps | 1 | 33% |
| Biopharma | 1 | 33% |
| Life Science | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 33% |
| Germany | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BioNTech | BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. | $325M | Series B | Jul 09, 2019 |  |
| Too Good To Go Denmark | Too Good To Go fights food waste primarily through our app. | $6.8M | Venture - Series Unknown | Feb 05, 2019 |  |
| BioNTech | BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. | $270M | Series A | Jan 04, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 2 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together
- [Athena Capital (South Africa)](https://shizune.co/investors/profile/athene-capital-south-africa) — VC Fund, 1 deal together
- [ATHOS Service](https://shizune.co/investors/profile/athos-service) — VC Fund, 1 deal together
- [BVCF](https://shizune.co/investors/profile/bioveda-china-fund) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Food and Beverage Investors in Denmark](https://shizune.co/investors/food-and-beverage-investors-denmark)
- [Food and Beverage Angel Investors in Denmark](https://shizune.co/investors/food-and-beverage-angel-investors-denmark)
- [Gaming Angel Investors in Denmark](https://shizune.co/investors/gaming-angel-investors-denmark)
- [Gaming Investors in Denmark](https://shizune.co/investors/gaming-investors-denmark)

## FAQ

### What does Mike Lee invest in?

Mike Lee invests primarily in Apps, Biopharma and Life Science startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mike Lee?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Mike Lee last invest?

The most recent investment recorded for Mike Lee closed in Jul 2019. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co